Leaflet OFOST 8.3mcg / ml solution for injection / infusion


Indicated for: uterine contractions; postpartum hemorrhage

Route of administration: injectable / infusion

Substance: oxytocin (uterotonic)

ATC: H01BB02 (Systemic hormonal preparations, excluding sex hormones and insulins | Posterior pituitary lobe hormones | Oxytocin and analogues)

Oxytocin is a hormone used in obstetrics to induce labor, stimulate uterine contractions, or control postpartum hemorrhage. It works by stimulating oxytocin receptors in the uterus, causing muscle contractions.

The medication is administered intravenously or intramuscularly, as directed by a doctor, usually in doses adjusted based on the patient's response. It is important for administration to be performed under strict medical supervision.

Patients should be aware of potential side effects, such as nausea, vomiting, or uterine hypertonia. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, vomiting, and uterine hypertonia. In rare cases, severe reactions such as uterine rupture or allergic reactions may occur. Patients should be informed of these risks before use.

General data about OFOST 8.3mcg / ml

  • Substance: oxytocin
  • Date of last drug list: 01-05-2026
  • Commercial code: W64163002
  • Concentration: 8.3mcg / ml
  • Pharmaceutical form: solution for injection / infusion
  • Quantity: 10
  • Product type: generic
  • Price: 28.89 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: AS GRINDEKS - LETONIA
  • Holder: AS GRINDEKS - LETONIA
  • Number: 10291/2017/02
  • Shelf life: 3 years

Concentrations available for oxytocin

  • 16.7mcg/ml
  • 1UI/ml
  • 5UI/ml
  • 8.3mcg/ml